FIGURE 1.

Low expression of methyltransferase‐like 14 (METTL14) is related to renal cell carcinoma (RCC) progression and poor prognosis. A, B, METTL14 mRNA (n = 47) and protein (n = 6) expression in RCC (T) and matched normal (N) tissues. C, METTL14 expression in KIRC from The Cancer Genome Atlas (TCGA) database (n = 533). D, E, Immunohistochemical (IHC) analysis of METTL14 in RCC tissue microarrays (n = 132). Magnification, 100×, 400×. F‐H, METTL14 expression in tumors >4 cm group (n = 100) vs tumors ≤4 cm group (n = 110), in the RCC with metastasis group (n = 50) vs RCC without metastasis group (n = 160), and in the Fuhrman I/II group (n = 144) vs Fuhrman III/IV group (n = 66). I, J, Kaplan‐Meier analysis of correlation between METTL14 and overall survival (OS) or recurrence‐free survival. K, Multivariate analysis of factors associated with OS in RCC patients (n = 210). L, Time‐dependent OS receiver operating characteristic (ROC) analysis. Error bars represent mean ± SD. Student’s t test (A, E‐H) and log‐rank test (I, J) were used. *P < .05, **P < .01, ***P < .001. AUC, area under the ROC curve; CI, confidence interval; HR, hazard ratio